Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview

Area of Science:

• Infectious Diseases
• Immunology
• Vaccinology

Background:

• Controlled human infection models (CHIMs) offer valuable insights into disease processes, pathogenesis, and immunity.
• CHIM studies are instrumental in assessing vaccine efficacy, significantly aiding vaccine development pipelines.
• The Shigella CHIM has been established across three US sites, poised for a key regulatory role.

Discussion:

• Harmonizing best practices across CHIM study sites is essential for maximizing data quality and comparability.
• Standardized protocols ensure robust and reproducible results, critical for regulatory decision-making.
• This harmonization effort aims to enhance the contribution of CHIM studies to Shigella vaccine advancement.

Key Insights:

• CHIMs provide a powerful platform for understanding host-pathogen interactions and immune responses.
• The Shigella CHIM is a vital tool for preclinical and clinical evaluation of Shigella vaccine candidates.
• Standardization of CHIM methodologies across multiple sites is critical for reliable efficacy assessments.

Outlook:

• Optimized CHIM protocols will accelerate the development and regulatory approval of effective Shigella vaccines.
• Continued refinement of CHIMs will broaden their application for other infectious agents.
• International collaboration in standardizing CHIM practices will further bolster global vaccine research efforts.